Herantis Pharma initiates patient recruitment for clinical study with Lymfactin® in breast cancer associated lymphedema

Herantis Pharma initiates patient recruitment for clinical study with Lymfactin® in breast cancer associated lymphedema

Herantis Pharma Plc
Company release 18 May 2016 at 9:00 am

Herantis Pharma Plc (“Herantis”) has started patient recruitment for its clinical study with Lymfactin® for the treatment of breast cancer associated secondary lymphedema. While the primary endpoint of the study is to assess the safety and tolerability of Lymfactin® the study will also assess the preliminary efficacy of the treatment.

(more…)

Read More

Herantis Pharma receives orphan designation of CDNF for treatment of ALS

Herantis Pharma receives orphan designation of CDNF for treatment of ALS

Herantis Pharma Plc
Company release 29 March 2016 at 9:00 am

The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the application of Herantis Pharma Plc (“Herantis”) for orphan drug designation of recombinant human Cerebral Dopamine Neurotrophic Factor (CDNF) for treatment of amyotrophic lateral sclerosis (ALS).

(more…)

Read More

Finnish Medicines Agency authorization of first-in-man clinical study with Lymfactin

Finnish Medicines Agency authorization of first-in-man clinical study with Lymfactin

Herantis Pharma Plc.
Company release 13 November 2015, 9:00 am

Finnish Medicines Agency Fimea has authorized Herantis Pharma Plc’s (“Herantis”) first-in-man clinical study of Lymfactin® for the treatment of breast-cancer associated lymphedema. Patient recruitment in the clinical study is planned to begin in Finland in the first half of 2016.

(more…)

Read More

Woodcast brings some colour to casting!

Woodcast brings some colour to casting! In addition to our regular Woodcast products we now have also red, blue, and black splints available.

Offer your patient a possibility to choose the colour of his/her orthosis. Woodcast splints are now available in four colours:

– Natural (natural Woodcast colour)
– Red
– Blue
– Black

Coloured splints are available in Woodcast 2 mm producs for casting and Woodcast Solid -products for occupational therapy.

Read More

Herantis Pharma granted almost 3 million Euro government loan for Parkinson study

Herantis Pharma granted almost 3 million Euro government loan for Parkinson study

Herantis Pharma Plc
Company release 30 June 2015 at 10:00 am

Tekes, the Finnish Funding Agency for Innovation, has granted a 2,903,000 EUR R&D loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally subject to obtaining regulatory approval for the clinical study.

(more…)

Read More

Herantis Pharma announces results from Phase 2 Cis-UCA Dry Eye study

Herantis Pharma announces results from Phase 2 Cis-UCA Dry Eye study

Herantis Pharma Plc
Company release 3 June 2015 at 8:00 am

Herantis Pharma Plc has completed its initial analysis of the results of its Phase 2 clinical study of cis-UCA in Dry Eye disease. When compared to placebo, cis-UCA did not show statistically significant improvements in the two co-primary endpoints for the treatment of signs and symptoms of Dry Eye after four weeks of treatment.

Statistically significant efficacy was seen in some secondary endpoints.

(more…)

Read More

Onbone Ltd raises €10M from international investor syndicate for the global launch of its novel casting/splinting products

Onbone Ltd, the developer of novel casting technology material, Woodcast®, has raised a total of €10 million in a financing round led by MVM Life Science Partners, with participation from Finnish Industry Investment, Finnish private investors and the existing investor Inveni Capital. The funding round will be used to finance the international launch of the Woodcast suite of casting and splinting products.

(more…)

Read More

Herantis Pharma’s Phase 2 Dry Eye study recruitment completed ahead of schedule

Herantis Pharma’s Phase 2 Dry Eye study recruitment completed ahead of schedule

Herantis Pharma Plc
Company release 11 March 2015 at 10:00 am

Herantis Pharma Plc has completed patient recruitment in its Phase 2 clinical study ahead of schedule. Also the number of recruited patients exceeded targets: A total of 161 patients were randomized in the study compared to the targeted 150 patients. The randomized patients will receive 4 weeks of treatment with either placebo eye drops or either of two different strengths of cis-UCA Eye Drops. The objective of the study is to compare the safety and efficacy of Cis-UCA Eye Drops to placebo, for the treatment of the signs and symptoms of Dry Eye Syndrome.

This study is conducted in the USA by Ora, Inc., the world’s leading independent, full-service ophthalmic clinical research and product development firm.

(more…)

Read More